Pharmaceutical

EU set to approve AstraZeneca’s Imfinzi-chemo combo for NSCLC

AstraZeneca's Imfinzi (durvalumab) plus chemotherapy, has gained CHMP recommendation for approval in the EU to treat NSCLC.

Mar 5, 2025 - 06:00
EU set to approve AstraZeneca’s Imfinzi-chemo combo for NSCLC
AstraZeneca's Imfinzi (durvalumab) plus chemotherapy, has gained CHMP recommendation for approval in the EU to treat NSCLC.
Read the original article

Tags:

Previous Article

Genentech wins FDA approval for second stroke treatment

Next Article

MWC Barcelona 2025: Huawei unveils global showcases alongside customers and laun...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Genentech wins FDA approval for second stroke treatment

Genentech wins FDA approval for second stroke treatment

Mar 5, 2025

STAT+: Pfizer plans to depart BIO

STAT+: Pfizer plans to depart BIO

Dec 5, 2023

An effort to diversify genetic research finds new variant for Parkinson’s disease in African populations

An effort to diversify genetic research finds new varia...

Aug 25, 2023